What To Do After the S&P 500 Erased 2025 Losses
On Tuesday, Nvidia (NVDA) said that it would sell 18,000 of its top-end artificial intelligence processors to Saudi Arabia customers. That sent NVDA stock up by 5.6%. It lifted the magnificent seven stocks, including Tesla (TSLA). It pushed the S&P 500 (IVV) back into positive returns for 2025.What should investors who missed the recent rally do?Investors who sold during the “Liberation Day” stock market panic may need to wait for stocks to pull back. However, the tariff trade war between the U.S. and China is easing. The U.S., for example, plans to cut the “de minimis” tariff for goods from China to as low as 30%. Officially, the de minimis duty is 54%, down from 120% after the trade negotiations in Geneva.This change will benefit package delivery firms, including FedEx (FDX), UPS (UPS), and DHL. Chinese e-commerce firms may also see orders rebound. The lower tariff helps Chinese retailers on PDD (PDD), which runs Temu, and Alibaba (BABA), which runs AliExpress.Inflation EasedIn April, the Bureau of Labor Statistics reported that the consumer price index increased 2.3% Y/Y. This is 10 bps below expectations. Lower inflation, a strong job market, and lower tariffs are all tailwinds for the economy.Investors may stay on course by holding their index ETFs. The chances are high for stock markets continuing on their uptrend.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


